Trending...
- B-Cide's New Track "CDPAP PPL Transition (Voice for the Disabled in New York)" Exposes Unspoken Crisis in Disability Care - 257
- Databahn Reveals Smart Sales Agent for Strategic Account Plans
- With Legionnaires' Cases Growing, New York Must Take a Comprehensive Approach to Address Disease
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In DexCom To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
More on Nyenta.com
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors the true state of DexCom's salesforce; notably, that it was not truly equipped to execute on the Company's perceived growth potential. Such statements absent these material facts caused Plaintiff and other shareholders to purchase DexCom's securities at artificially inflated prices.
On July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on their execution of "several key strategic initiatives" which "did not meet [their] high standards."
Investors and analysts reacted immediately to DexCom's revelation. The price of DexCom's common stock declined dramatically. From a closing market price of $107.85 per share on July 25, 2024, DexCom's stock price fell to $64.00 per share on July 26, 2024, a decline of about 40.66% in the span of just a single day.
More on Nyenta.com
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information Dexcom's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Dexcom class action, go to www.faruqilaw.com/DXCM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
If you suffered losses exceeding $100,000 in DexCom between January 8, 2024 to July 25, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DexCom, Inc. ("DexCom" or the "Company") (NASDAQ:DXCM) and reminds investors of the October 21, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
More on Nyenta.com
- Bookmakers Review: Shohei Ohtani Leads 2025 TIME Athlete of the Year Betting Market
- Materna Health to Open NYC's First Early Pregnancy Care Center
- Provident Healthcare Partners Advises Elder Care Homecare on its Partnership with Rallyday Partners
- OddsTrader Releases 2025-26 NFL Passing Leader Odds — Can Anyone Top Joe Burrow?
- Holidaily Brewing Co. Ranks No. 723 on 2025 Inc. 5000 List of Fastest-Growing U.S. Private Companies
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors the true state of DexCom's salesforce; notably, that it was not truly equipped to execute on the Company's perceived growth potential. Such statements absent these material facts caused Plaintiff and other shareholders to purchase DexCom's securities at artificially inflated prices.
On July 25, 2024, Dexcom announced its financial results for the second quarter of fiscal 2024 and reduced its revenue guidance for the full fiscal year 2024. The Company attributed its results and lowered guidance on their execution of "several key strategic initiatives" which "did not meet [their] high standards."
Investors and analysts reacted immediately to DexCom's revelation. The price of DexCom's common stock declined dramatically. From a closing market price of $107.85 per share on July 25, 2024, DexCom's stock price fell to $64.00 per share on July 26, 2024, a decline of about 40.66% in the span of just a single day.
More on Nyenta.com
- One Shake, Two Solutions – Sleep Protein™ Targets America's Sleep and Recovery Crisis
- The Community-Police Relations Foundation Announces Strategic Partnership with Broadstreet Global and EEP Law to Promote Community Safety and Unity
- Honoring the Legacy of the Montford Point Marines
- Genpak Increases Foodservice Packaging Efficiency for Emerging Restaurants
- Where You Play Matters: MrBet Decodes Europe's Complex Gambling Tax Rules in New Report
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information Dexcom's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Dexcom class action, go to www.faruqilaw.com/DXCM or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- ABISA Advises Precision Cancer Care
- St. Paul, Mn Goes Ninja: Emmy-winning Naruto Star Maile Flanagan Headlines Inaugural Anime Wonder Fest
- FDA Fast Track Designation for $3 Billion Suicidal Depression Market May Soon be Accessible for Effective NRX 100 Drug Therapy: NRx Pharmaceuticals
- Bit Digital, Inc. Announces Date for Second Quarter 2025 Financial Results and Conference Call
- Consumer Attorneys Secures $53,250 Settlement for Client in Consumer Report Mix-Up
- United States Millwork Market to Hit USD 18.4 Billion by 2032
- Slotozilla Expands Partner Network With 25+ Affiliates and Unveils 139 New Bonuses in Q2 2025
- Djamee Defies Industry Machine With Ai-powered Debut Bkk X Nyc
- Who the Hell is Cloud9 Network—And Why Is Everyone Suddenly Watching?
- Newport Heights' Most Coveted Coastal Estate
- AI Where the Data Lives – Q&A; with Jose Carlos Moreira, HL Tech Group LLC
- A Quality 4.0 roadmap is now available!
- ShariaLending.org Powered by AdamMoney, Unveils First-Ever 0% Interest, 0 Fee, Non-Recourse loans
- Bay Miner Unveils Crypto Mining App to Help Investors Seize 2025's XRP Compliance Investment Opportunities
- Rooted Relief Unveils Breakthrough Holistic Healing Method for Neuropathy
- Arms Preservation Inc Offers Industry-Leading VCI Firearm Storage Bags for Superior Rust Prevention
- Faruqi & Faruqi Reminds Petco Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 29, 2025 - WOOF
- Savoy Foundation's 19th Annual Savoy Lecture Series
- TUNL UNITES WITH STREET DREAMS AND ARTE HAUS TO LAUNCH NEW SPORTS & FASHION COLLECTIVE
- Final Clearance to Close Dura Medical Acquisition from Florida's Agency for Health Care Administration (AHCA); $750 Million Ketamine Therapy Market